ADDvise receives allocation decision worth approximately MSEK 2.2 – Regulatory information

26-02-2020   Regulatory press release

ADDvise Group AB (publ) subsidiary Sonar Oy has received an allocation decision from Kangasala town in Finland worth approximately MSEK 2.2. The allocation decision consists of an order, and with the possibility for a second order with the same value, regarding a digital radiography (DR) system used for image capturing.

The decision is subject to an appeal time expiring 11 March 2020.

ADDvise Group AB (publ) has adopted new guidelines regarding the assessment of information affecting the financial instrument and the disclosure thereof. Entailing that orders and investments within the group with an aggregate value of at least MSEK 5 are to be considered as information affecting the financial instrument and shall be published to the market through a press release. However, the assessment of whether the information may affect the financial instrument is based on the facts and circumstances in the specific case.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on February 26, 2020 at 17:25 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50,, is the Company's Certified Adviser. Additional information is available at

Latest press releases

ADDvise announces preliminary result for 2022 which is stronger than expected


The preliminary result for ADDvise Group for the full year 2022 significantly deviates from what ADDvise Group considers to be current market expectations. [image] The net sales pro forma full year 2022 rolling 12 months amounted to SEK 1,097 million with an adjusted EBITDA pro forma of SEK 241 million. The financial targets for the…

ADDvise receives order worth USD 3.5 million


ADDvise Group AB’s subsidiary Poly Pharmaceuticals Inc has received an order from AxisCare Health Logistics Inc, a company distributing equipment and medical supplies to hospitals, clinics, medical offices and medical equipment suppliers. The order is worth approximately USD 3.5 million. The order consists of delivery of the prescription dietary supplemental Folite, developed and manufactured by…

ADDvise receives order worth USD 1.8 million


ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Nasser Saeed Al Hajri & Partners Contracting (NHS & Partners), a leading construction contractor in the United Arab Emirates. The order is worth approximately USD 1.8 million. The order involves the detailed design, supply and installation of an ISO 8 and ISO 7…